Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis
J. Clin. Invest. Laurence M. Howard, et al. 109:233 doi:10.1172/JCI14374 [Go to this article.]

Figure 2
Short-term anti-CD154 therapy inhibits in vivo PLP139-151–specific antibody and DTH responses. Mice were immunized with PLP139-151/CFA and treated with control Ig or anti-CD154 as described in Figure 1. (a) Sera obtained from mice 25 days after immunization were analyzed for anti–PLP139-151–specific IgG levels. Data were obtained from five serological samples combined from two separate experiments. (b) PLP139-151–specific DTH responses were measured at 100 days after immunization. Data presented are the combined results from two separate experiments, and the number of mice in each group is marked below each bar. *DTH response was significantly less (P < 0.05) in anti-CD154–treated mice.